Compare Pfizer with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs PANACEA BIOTECH - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER PANACEA BIOTECH PFIZER/
PANACEA BIOTECH
 
P/E (TTM) x 38.5 9.6 402.7% View Chart
P/BV x 6.5 2.0 321.2% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 PFIZER   PANACEA BIOTECH
EQUITY SHARE DATA
    PFIZER
Mar-19
PANACEA BIOTECH
Mar-19
PFIZER/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs3,840354 1,086.0%   
Low Rs2,080138 1,505.1%   
Sales per share (Unadj.) Rs455.074.6 610.2%  
Earnings per share (Unadj.) Rs93.86.7 1,404.1%  
Cash flow per share (Unadj.) Rs109.415.5 705.9%  
Dividends per share (Unadj.) Rs22.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs658.257.2 1,150.6%  
Shares outstanding (eoy) m45.7561.25 74.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.53.3 197.3%   
Avg P/E ratio x31.636.8 85.7%  
P/CF ratio (eoy) x27.115.9 170.5%  
Price / Book Value ratio x4.54.3 104.6%  
Dividend payout %24.00-   
Avg Mkt Cap Rs m135,42015,061 899.1%   
No. of employees `0002.62.3 113.7%   
Total wages/salary Rs m3,2381,471 220.2%   
Avg. sales/employee Rs Th7,911.41,973.6 400.9%   
Avg. wages/employee Rs Th1,230.9635.6 193.7%   
Avg. net profit/employee Rs Th1,630.7176.8 922.4%   
INCOME DATA
Net Sales Rs m20,8154,567 455.8%  
Other income Rs m1,67445 3,736.4%   
Total revenues Rs m22,4894,612 487.6%   
Gross profit Rs m5,7122,030 281.4%  
Depreciation Rs m714540 132.2%   
Interest Rs m731,048 7.0%   
Profit before tax Rs m6,599486 1,357.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,30977 2,994.3%   
Profit after tax Rs m4,291409 1,048.8%  
Gross profit margin %27.444.4 61.7%  
Effective tax rate %35.015.9 220.6%   
Net profit margin %20.69.0 230.1%  
BALANCE SHEET DATA
Current assets Rs m27,1672,415 1,125.1%   
Current liabilities Rs m8,9179,077 98.2%   
Net working cap to sales %87.7-145.9 -60.1%  
Current ratio x3.00.3 1,145.4%  
Inventory Days Days6865 104.2%  
Debtors Days Days3071 42.4%  
Net fixed assets Rs m8,8628,333 106.3%   
Share capital Rs m45861 746.3%   
"Free" reserves Rs m29,6563,443 861.4%   
Net worth Rs m30,1133,504 859.4%   
Long term debt Rs m25461 5.4%   
Total assets Rs m39,40013,755 286.4%  
Interest coverage x91.51.5 6,252.4%   
Debt to equity ratio x00.1 0.6%  
Sales to assets ratio x0.50.3 159.1%   
Return on assets %11.110.6 104.5%  
Return on equity %14.211.7 122.0%  
Return on capital %22.138.7 57.2%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m4281,203 35.6%   
Fx outflow Rs m786467 168.5%   
Net fx Rs m-358736 -48.6%   
CASH FLOW
From Operations Rs m9781,049 93.3%  
From Investments Rs m351-54 -656.4%  
From Financial Activity Rs m-1,099-1,011 108.6%  
Net Cashflow Rs m231-20 -1,171.6%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 0.6 1,250.0%  
FIIs % 4.9 1.3 376.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 23.6 100.4%  
Shareholders   85,207 10,259 830.6%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ALEMBIC PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare PFIZER With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Auto and Energy Stocks Witness Buying(Closing)

Indian share markets ended their volatile trading day on a flattish note. At the closing bell, the BSE Sensex stood higher by 42 points (up 0.1%).

Related Views on News

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

This PSU Turned into a Rare 100 Bagger. Others May Follow.(The 5 Minute Wrapup)

Nov 27, 2019

The lowest hanging fruit for government to raise capital would be to sell off stakes in non-critical PSUs.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Dec 9, 2019 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS